WO2005056766A3 - TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES - Google Patents
TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES Download PDFInfo
- Publication number
- WO2005056766A3 WO2005056766A3 PCT/US2004/041020 US2004041020W WO2005056766A3 WO 2005056766 A3 WO2005056766 A3 WO 2005056766A3 US 2004041020 W US2004041020 W US 2004041020W WO 2005056766 A3 WO2005056766 A3 WO 2005056766A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- epha2
- therapeutic
- composition
- hyperproliferative
- nucleic acid
- Prior art date
Links
- 108010055196 EphA2 Receptor Proteins 0.000 title abstract 5
- 102000051096 EphA2 Receptor Human genes 0.000 title abstract 5
- 238000012377 drug delivery Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 230000003463 hyperproliferative effect Effects 0.000 abstract 6
- 239000003795 chemical substances by application Substances 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 5
- 230000000069 prophylactic effect Effects 0.000 abstract 4
- 230000001225 therapeutic effect Effects 0.000 abstract 4
- 108010055179 EphA4 Receptor Proteins 0.000 abstract 3
- 102000021727 EphA4 Receptor Human genes 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 230000008685 targeting Effects 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000007726 management method Methods 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102000050554 Eph Family Receptors Human genes 0.000 abstract 1
- 108091008815 Eph receptors Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52739603P | 2003-12-04 | 2003-12-04 | |
US60/527,396 | 2003-12-04 | ||
US11/004,794 | 2004-12-03 | ||
US11/004,794 US20050153923A1 (en) | 2003-12-04 | 2004-12-03 | Targeted drug delivery using EphA2 or EphA4 binding moieties |
US11/004,795 | 2004-12-03 | ||
US11/004,795 US20050147593A1 (en) | 2003-05-22 | 2004-12-03 | EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005056766A2 WO2005056766A2 (en) | 2005-06-23 |
WO2005056766A3 true WO2005056766A3 (en) | 2008-01-31 |
Family
ID=34682013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/041020 WO2005056766A2 (en) | 2003-12-04 | 2004-12-06 | TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005056766A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
US7662770B2 (en) | 2002-05-23 | 2010-02-16 | Purdue Research Foundation | Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic target |
EP1617864A4 (en) * | 2003-04-11 | 2006-06-21 | Medimmune Inc | Epha2 and non-neoplastic hyperproliferative cell disorders |
EP1618184A4 (en) * | 2003-04-11 | 2006-06-21 | Medimmune Inc | Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution |
AU2004291026A1 (en) * | 2003-06-06 | 2005-06-02 | Medimmune, Llc | Use of EphA4 and modulator of EphA4 for diagnosis, treatment and prevention of cancer |
JP4860477B2 (en) * | 2003-11-20 | 2012-01-25 | メディミューン,エルエルシー | EphA2 agonistic monoclonal antibody and method of use thereof |
WO2006026820A1 (en) * | 2004-09-08 | 2006-03-16 | The University Of Queensland | Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor |
CA2644743C (en) * | 2006-03-08 | 2015-05-19 | Waldemar Debinski | Soluble monomeric ephrin a1 |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
ES2447868T3 (en) | 2007-03-14 | 2014-03-13 | Bionsil S.R.L. In Liquidazione | BTK inhibitors for use in the treatment of epithelial tumors resistant to chemotherapeutic drugs |
PT2199390T (en) | 2007-08-30 | 2017-03-15 | Daiichi Sankyo Co Ltd | Anti-epha2 antibody |
JP5808349B2 (en) | 2010-03-01 | 2015-11-10 | カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー | Biomarkers for theranosis |
KR20130043104A (en) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | Circulating biomarkers for disease |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040028685A1 (en) * | 2002-05-10 | 2004-02-12 | Kinch Michael S. | EphA2 monoclonal antibodies and methods of use thereof |
US20040180823A1 (en) * | 2002-09-24 | 2004-09-16 | Pasquale Elena B. | Novel agents that modulate Eph receptor activity |
US6927203B1 (en) * | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
-
2004
- 2004-12-06 WO PCT/US2004/041020 patent/WO2005056766A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6927203B1 (en) * | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
US20040028685A1 (en) * | 2002-05-10 | 2004-02-12 | Kinch Michael S. | EphA2 monoclonal antibodies and methods of use thereof |
US20040180823A1 (en) * | 2002-09-24 | 2004-09-16 | Pasquale Elena B. | Novel agents that modulate Eph receptor activity |
Non-Patent Citations (10)
Title |
---|
BRANTLEY ET AL.: "Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo", ONCOGENE, vol. 21, 2002, pages 7011 - 7026 * |
CARLES-KINCH ET AL.: "Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior", CANCER RESEARCH, vol. 62, May 2002 (2002-05-01), pages 2840 - 2847 * |
CHENG ET AL.: "Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors", NEOPLASIA, vol. 5, no. 5, 2003, pages 445 - 456 * |
CHENG ET AL.: "The Ephrins and Eph receptors in angiogenesis", CYTOKINE & GROWTH FACTOR REVIEWS, vol. 13, 2002, pages 75 - 85 * |
CROSASSO ET AL.: "Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs", J. OF PHARMACEUTICAL SCIENCES, vol. 86, no. 7, July 1997 (1997-07-01), pages 832 - 839 * |
EASTY ET AL.: "Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma", INT. J. CANCER, vol. 71, 1997, pages 1061 - 1065 * |
KOOLPE ET AL.: "An ephrin mimetic peptide that selectively targets the EphA2 receptor", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 49, 2002, pages 46974 - 46979 * |
MERIC ET AL.: "Expression profile of tyrosine kinases in breast cancer", CLINICAL CANCER RESEARCH, vol. 8, 2002, pages 361 - 367 * |
OGAWA ET AL.: "The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization", ONCOGENE, vol. 19, 2000, pages 6043 - 6052 * |
ZELINSKI ET AL.: "EphA2 overexpression causes tumorigenesis of mammary epithelial cells", CANCER RESEARCH, vol. 61, 2001, pages 2301 - 2306 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005056766A2 (en) | 2005-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005055948A3 (en) | Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders | |
WO2006113623A3 (en) | Elimination of heterogeneous or mixed cell population in tumors | |
WO2004111192A3 (en) | Targeted delivery to legumain-expressing cells | |
WO2004105782A3 (en) | Drug delivery systems for tumor targeting ngr-molecules and uses thereof | |
WO2005056766A3 (en) | TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES | |
WO2008036682A3 (en) | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates | |
WO2007143316A3 (en) | Compounds and methods for modulating expression of sglt2 | |
WO2008091375A3 (en) | Attenuated salmonella as a delivery system for sirna-based tumor therapy | |
WO2006039704A3 (en) | Pharmaceutical composition and method for treating a joint capsule arthropathy | |
MX339142B (en) | Combinations and modes of administration of therapeutic agents and combination therapy. | |
WO2007008463A3 (en) | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment | |
WO2008039218A3 (en) | Inhibitors of bruton's tyrosine kinase | |
WO2007118245A8 (en) | Methods and compositions related to adenoassociated virus-phage particles | |
US9080173B2 (en) | Methods and compositions for RNAi-based cancer treatment | |
WO2007059342A3 (en) | Random copolymer compositions for treating unwanted immune response | |
WO2006138608A3 (en) | Pharmaceutical compositions and use thereof | |
WO2005094899A8 (en) | Clusterin antisense therapy for treatment of cancer | |
WO2008097927A3 (en) | Treatment and prevention of neurodegenerative diseases using gene therapy | |
WO2007078443A3 (en) | Methods of treating unwanted immune response with random copolymers | |
WO2005115360A3 (en) | Formulations of anti-pain agents and methods of using the same | |
WO2005120542A3 (en) | Methods of treating disease with random copolymers | |
WO2005046593A3 (en) | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. | |
WO2004043378A3 (en) | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | |
WO2006115770A3 (en) | Orally disintegrating pharmaceutical tablet formulations of olanzapine | |
WO2005009394A3 (en) | Drug delivery in the nervous system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |